Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance range Exciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key upcoming events, including Phase 3 results for …